PharmaLex expands global footprint capabilities for clinical and regulatory services with Phlexglobal merger

PharmaLex expands global footprint capabilities for clinical and regulatory services with Phlexglobal merger
 
Merger continues commitment to innovation and strengthens tech-enablement and automation

 

Frankfurt, Germany – 25 January 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced a merger with leading technology and services organization for clinical and regulatory solutions, Phlexglobal.

 

Founded in 1997, Phlexglobal provides its industry-leading and innovative electronic Trial Master File platform (PhlexTMF) and services to hundreds of global life sciences companies and AI-enabled automation solutions that allow customers to benefit from existing clinical and regulatory training models.

 

Phlexglobal’s staff of more than 400 people – based in the United Kingdom, the United States, India, Poland and Germany – bring their highly valued technical skills, along with the company’s established market footprint, to the PharmaLex portfolio.  The Phlexglobal merger comes with state-of-the art technology capabilities, including a regulatory information management system, which will be used to support PharmaLex’s overall comprehensive global solutions.

 

“The merger with PharmaLex provides our clients and the life sciences industry with access to a more robust combined set of capabilities across all of our key value areas,” said John McNeill, CEO of Phlexglobal.”  With our shared focus on streamlining the overall development process as well as our cultural values, both Phlexglobal and PharmaLex will deliver greater value to customers.”

 

“We are delighted to welcome the Phlexglobal team to the PharmaLex Group, and the opportunity to continue our commitment to innovation by further expanding our technology-enabled service solutions portfolio with the addition of Phlexglobal’s capabilities for eTMF technology and services, as well as their state-of-the-art regulatory operations and automation technologies,” said PharmaLex CEO Dr. Thomas Dobmeyer. “The merger enables us to further our goal of becoming a technology-enabled solution provider, and at the same time increasing operational excellence and efficiency through our global subject matter expertise.”